Gamida Cell is a leader in cellular and immune therapeutics, committed to changing the treatment paradigm for patients with cancer and rare genetic diseases. We are building a broad pipeline based on our proprietary NAM technology platform. Our lead program, NiCord, is in phase 3 development for allogeneic bone marrow transplantation and was granted Breakthrough Therapy Designation by the FDA.